|
|
|
Volumn 5, Issue 1, 2002, Pages 6-13
|
|
Bad medicine: Why the generic drug regulatory paradigm is inapplicable to biotechnology products
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABCIXIMAB;
ALGLUCERASE;
ALLERGEN;
AMOXICILLIN PLUS CLAVULANIC ACID;
ANTIBIOTIC AGENT;
ANTIBODY;
BETA1A INTERFERON;
BIOLOGICAL PRODUCT;
DORNASE ALFA;
ENZYME;
ERYTHROPOIETIN;
ETANERCEPT;
FLUOXETINE;
GENERIC DRUG;
HORMONE;
HUMAN GROWTH HORMONE;
INDINAVIR;
INTERFERON BETA SERINE;
INTERLEUKIN 2 RECEPTOR ANTIBODY;
LEVOTHYROXINE;
LORATADINE;
METFORMIN;
PACLITAXEL;
PAROXETINE;
POLYNUCLEOTIDE;
PROTEIN;
RANITIDINE;
RECOMBINANT ALPHA2A INTERFERON;
RECOMBINANT ALPHA2B INTERFERON;
RECOMBINANT ERYTHROPOIETIN;
RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;
RITUXIMAB;
ROFECOXIB;
SIMVASTATIN;
UNINDEXED DRUG;
UNITHROID;
VACCINE;
BIOEQUIVALENCE;
BIOTECHNOLOGY;
CLINICAL TRIAL;
DRUG EFFICACY;
DRUG LEGISLATION;
DRUG MANUFACTURE;
DRUG MARKETING;
DRUG POTENCY;
DRUG PURITY;
DRUG QUALITY;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
MOLECULAR SIZE;
REVIEW;
|
|
EID: 0036199096
PISSN: 10955127
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (8)
|
|
References (0)
|